Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b/3 Study of IIBR-100 (BriLife) Vaccine vs Approved Vaccine for COVID-19
NCT04990466Phase 3Withdrawn
- Sponsor
- NRx Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Viral Vector Vaccines, Fc-Fusion Proteins
01
Overview
A Phase 3 trial of Brilife in coronavirus disease 2019 (COVID-19), sponsored by NRx Pharmaceuticals. Planned start Sep 2021; status: withdrawn.
02
Drugs
Brilife
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04990466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990466.